Abelmoschus manihot – a traditional Chinese medicine versus losartan potassium for treating IgA nephropathy: study protocol for a randomized controlled trial
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Abelmoschus manihot – a traditional Chinese medicine versus losartan potassium for treating IgA nephropathy: study protocol for a randomized controlled trial
Authors
Keywords
IgA nephropathy, Traditional Chinese medicine, <em class=EmphasisTypeItalic >Abelmoschus manihot</em>, Randomized controlled study
Journal
Trials
Volume 18, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-04-11
DOI
10.1186/s13063-016-1774-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Recent Advances in Traditional Chinese Medicine for Kidney Disease
- (2015) Yifei Zhong et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- New developments in the genetics, pathogenesis, and therapy of IgA nephropathy
- (2015) Riccardo Magistroni et al. KIDNEY INTERNATIONAL
- Intensive Supportive Care plus Immunosuppression in IgA Nephropathy
- (2015) Thomas Rauen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Conjugated metabolites represent the major circulating forms ofAbelmoschus manihot in vivoand show an altered pharmacokinetic profile in renal pathology
- (2015) Jianming Guo et al. PHARMACEUTICAL BIOLOGY
- Metabolite identification strategy of non-targeted metabolomics and its application for the identification of components in Chinese multicomponent medicine Abelmoschus manihot L.
- (2015) Jian-ming Guo et al. PHYTOMEDICINE
- Efficacy and Safety of Abelmoschus manihot for Primary Glomerular Disease: A Prospective, Multicenter Randomized Controlled Clinical Trial
- (2014) Li Zhang et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Efficacy and safety of Flos Abelmoschus manihot (Malvaceae) on type 2 diabetic nephropathy: A systematic review
- (2014) Yi-zhi Chen et al. Chinese Journal of Integrative Medicine
- Efficacy and Safety of Traditional Chinese Medicine (Shenqi Particle) for Patients With Idiopathic Membranous Nephropathy: A Multicenter Randomized Controlled Clinical Trial
- (2013) Yiping Chen et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Glomerulonephritis
- (2013) Laurence Beck et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Reporting of Noninferiority and Equivalence Randomized Trials
- (2013) Gilda Piaggio et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Simultaneous Determination of Seven Active Flavonols in the Flowers of Abelmoschus manihot by HPLC
- (2013) X. Lai et al. JOURNAL OF CHROMATOGRAPHIC SCIENCE
- Huangkui capsule, an extract from Abelmoschus manihot (L.) medic, ameliorates adriamycin-induced renal inflammation and glomerular injury via inhibiting p38MAPK signaling pathway activity in rats
- (2013) Yue Tu et al. JOURNAL OF ETHNOPHARMACOLOGY
- IgA Nephropathy
- (2013) Robert J. Wyatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
- (2013) A.-W. Chan et al. BMJ-British Medical Journal
- Corticosteroid Therapy in IgA Nephropathy
- (2012) J. Lv et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Screening for in vitro metabolites of Abelmoschus manihot extract in intestinal bacteria by ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry
- (2011) Caifu Xue et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Estimating GFR Using the CKD Epidemiology Collaboration (CKD-EPI) Creatinine Equation: More Accurate GFR Estimates, Lower CKD Prevalence Estimates, and Better Risk Predictions
- (2010) Andrew S. Levey et al. AMERICAN JOURNAL OF KIDNEY DISEASES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started